Evidence map›Paper›PMID 38297224›Full record

ArticleBMC infectious diseases2024

First COVID-19 wave in the province of Bergamo, Italy: epidemiological and clinical characteristics, outcome and management of the first hospitalized patients.

Bianca Maria Donida, Flavia Simonetta Pirola, Roberto Opizzi, Peter Assembergs

Abstract read
In one paragraph

Article in BMC infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Bianca Maria DonidaASST Bergamo Ovest, Treviglio (BG), Italy. bianca_donida@asst-bgovest.it.
Flavia Simonetta PirolaASST Bergamo Ovest, Treviglio (BG), Italy.
Roberto OpizziASST Bergamo Ovest, Treviglio (BG), Italy.
Peter AssembergsASST Bergamo Ovest, Treviglio (BG), Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNorthern Italy was the first European country affected by the spread of the SARS-CoV-2, with the epicenter in the province of Bergamo.

aimThis study aims to analyze the characteristics of patients who experienced more severe symptoms during the first wave of COVID-19 pandemic. MATERIALS AND

methodsWe retrospectively collected epidemiological and clinical data on patients with laboratory-confirmed wild-type SARS-CoV-2 infection who were admitted to the "ASST Bergamo Ovest" hospital between February 21 and May 31, 2020.

resultsA total of seven hundred twenty-three inpatients met the eligible criteria and were included in the study cohort. Among the inpatients who survived, the average hospital length of stay was more than two weeks, with some lasting up to three months. Among the 281 non-survivors, death occurred in 50% within five days. Survivors were those whose first aid operators recorded higher oxygen saturation levels at home. The request for first aid assistance came more than one week after symptom onset, within three days in 10% of cases.

conclusionIn similar future scenarios, based on our data, if we aim to enhance the survival rate, we need to improve the territorial healthcare assistance and admit to hospitals only those patients who are at risk of severe illness requiring specialized and urgent interventions within two, three, or, at most, five days from the onset of symptoms. This implies that the crucial factor is, has been, and will be the ability of a healthcare system to react promptly in its entirety within a few days.

Indexed as

COVID-19HumansItalyPandemicsRetrospective StudiesSARS-CoV-2

Identifiers

PMID38297224
PMCPMC10829314

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.